DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Liprotamase

Phase Three

Phase Three

Therapeutic Approach

Nutritional-GI

Liprotamase (Sollpura) is a pancreatic enzyme replacement that is not prepared from animal sources.

Status

An ongoing Phase 3 trial, will look at the safety and effectiveness for people with CF ages 7 years and older. A previous Phase 3 trial showed that there were no safety concerns, and the coefficient of fat absorption improved.

Sponsor

The program is sponsored by Anthera Pharmaceuticals and partially funded by Cystic Fibrosis Foundation Therapeutics. It is being conducted within CFFT's Therapeutics Development Network.

Contact us about Liprotamase >